MedTrace Logo

Intranasal Dexmedetomidine Versus Intravenous Dexmedetomidine for Improving Quality of Endoscopic Sinus Surgery

NCT06081933 · Status: UNKNOWN · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 54

Last updated 2023-10-13

No results posted yet for this study

Summary

compare intranasal dexmedetomidine versus intravenous dexmedetomidine for improving quality of the operative field in Functional endoscopic sinus surgery

Conditions

  • Dexmedetomidine
  • Functional Endoscopic Sinus

Interventions

DRUG

intranasal dexmedetomidine

Patients will receive 1.5 micro g/kg intranasal dexmedetomidine diluted with saline + infusion saline

DRUG

intravenous dexmedetomidine

patients will receive 0.1- 0.4 micro g/kg intravenous infusion dexmedetomidine + intranasal saline.

Sponsors & Collaborators

  • Kafrelsheikh University

    lead OTHER

Principal Investigators

  • Kamal Ebeid, MD · Lecturer of Otorhinolaryngology, Faculty of medicine, Tanta University, Egypt

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-12-20
Primary Completion
2023-12-15
Completion
2023-12-15

Countries

  • Egypt

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06081933 on ClinicalTrials.gov